A report from DelveInsight highlights over 20 companies developing 22 treatments for myotonic dystrophy, with progress in ...
Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa ...
The first iteration of the European Shortages Monitoring Platform (ESMP) has gone live. Using this version of the ESMP, marketing authorization holders (MAHs) can submit data to routinely report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback